Genetically engineered oncolytic immunotherapy with a two-pronged attack on cancer

Oncolytic immunotherapy is a form of cancer treatment that uses genetically modified viruses to preferentially kill cancer cells and generate anti-tumor immune responses. Our agent, CG0070, is at the forefront of this field, leading a two-pronged attack against cancer through both direct and indirect killing.​


CG0070 is a modified adenovirus type 5 (Ad5) carrying: (I) an E2F-1 promoter upstream of an E1A promoter, and (II) the gene for GM-CSF. The first modification enables the virus to selectively target and replicate in cancer cells.

Following replication and lysis, the second modification enables the release of GM-CSF alongside tumor-specific antigens and other danger signals such as PAMPs and DAMPs.​

Adaptive Immune Response

GM-CSF operates by activating dendritic cells, which collect tumor antigens and present them to cytotoxic and helper T cells - triggering their maturation.

These T cells are then able to circulate throughout the body, recognizing and attacking residual cancer.

Through this dual mechanism, CG0070 not only increases its attack on cancer but also fights to deter its spread and recurrence in the future.


Phase II Multi Center Study of the Safety and Efficacy of CG0070 Oncolytic Vector Regimen in Patients with BCG-unresponsive Non–Muscle-Invasive Bladder Cancer (pdf)
Vignesh Packiam, Donald Lamm, Daniel Barocas, Andrew Trainer, Benjamin Fand, Ronald Davis III, William Clark, Michael Kroeger, Igor Dumbadze, Karim Chamie, A. Karim Kader, Dominic Curran, John Gutheil, Arthur Kuan, Alex W. Yeung, Gary Steinberg
Urologic Oncology: Seminars and Original Investigations 2017

Infectious Enthusiasm (pdf)
Emily Cukier-Meisner
BioCentury, 2016

Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity
Zong Sheng Guo, Zuqiang Liu, and David L. Bartlett
Frontiers in Oncology, 4:74, 2014

Activity of intravesical CG0070 in Rb-inactive superficial bladder cancer after BCG failure: Updated results of a phase I/II trial
Terence W. Friedlander, Vivian K. Weinberg, Alex Yeung, James Burke, Donald L. Lamm, James M. McKiernan, John J. Nemunaitis, Joe Stephenson, Eric Jay Small, Lawrence Fong, Maxwell V. Meng
ASCO Annual Meeting, June 2012, Chicago, IL

A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer (pdf)
James M. Burke, Donald L. Lamm, Maxwell V. Meng, John J. Nemunaitis, Joseph J. Stephenson, James C. Arseneau, Junko Aimi, Seth Lerner, Alex W. Yeung, Troy Kazarian, Daniel J. Maslyar, and James M. McKiernan
The Journal of Oncology, 188(6):2391-7, 2012

A Phase 1 Dose-Escalation Trial of Intravesical CG0070 for Superficial Transitional Cell Carcinoma (TCC) of the Bladder after Bacillus Calmette-Guerin (BCG) Failure (pdf)
Neil Senzer, John Nemunaitis, Michael Goldstein, James Arseneau, Don Lamm, Joe Stephenson, Harry Tsai, Kristina Neal, Junko Aimi, D.C. Yu, Daniel Maslyar, John Corman, James Mckiernan and James Burke
Molecular Therapy, 13, 2006

CG0070, a Conditionally Replicating Granulocyte Macrophage Colony-Stimulating Factor Armed Oncolytic Adenovirus for the Treatment of Bladder Cancer (pdf)
Nagarajan Ramesh, Ying Ge, David L. Ennist, Mingzhu Zhu, Mervat Mina, Shanthi Ganesh, P. Seshidhar Reddy, De-Chao Yu
Clinical Cancer Research, 12(1):305-13, 2006

An Oncolytic Adenovirus Selective for Retinoblastoma Tumor Suppressor Protein Pathway-defective Tumors: Dependence on E1A, the E2F-1 Promoter, and Viral Replication for Selectivity and Efficacy (pdf)
John L. Jakubczak, Patricia Ryan, Mario Gorziglia, Lori Clarke, Lynda K. Hawkins, Carl Hay, Ying Huang, Michele Kaloss, Anthony Marinov, Sandrina Phipps, Anne Pinkstaff, Pamela Shirley, Yelena Skripchenko, David Stewart, Suzanne Forry-Schaudies, and Paul L. Hallenbeck
Cancer Research, 63(7):1490-9, 2003